HCP 16
Medical Oncologist · United Kingdom · Consultant
Illustrative synthetic data for prototype demonstration — not real clinical findings.
Discussion summary
Conditionally positive; wants clarity on patient selection and comparative positioning.
Key themes
Pre / post perception
Overall perception shiftNo matched pre/post perception for this HCP
This conversation is not part of the matched pre/post perception sample, so a before-and-after comparison is not available. Their qualitative positions above still reflect what they said at congress.
KBQs discussed
Position against each predefined questionClinical significance of the primary endpoint
What is the expert consensus regarding the clinical significance of the study’s primary endpoint results?
“The effect size here is hard to ignore — for the patients I see this is a genuinely meaningful result.”
Safety, tolerability and willingness to prescribe
How do HCP perceptions of the trial’s safety and tolerability profile impact their willingness to adopt and prescribe the treatment?
“How the patient feels week to week matters as much as the efficacy for me.”
Use in node-positive populations
What is the clinical consensus among HCPs regarding the use of CDK4/6 inhibitors in node-positive patient populations?
Sequencing after adjuvant recurrence
How do clinicians approach treatment sequencing following recurrence on an adjuvant CDK4/6 inhibitor?
“If they have progressed on the class, continuing it rarely makes sense to me.”
Compelling nature of the primary endpoint
How compelling are the primary endpoint findings in driving prospective prescribers to select this treatment over existing options?
“It is a welcome result, but on its own it does not yet displace what I use first.”
Perception of safety and tolerability
How do experts perceive the safety and tolerability profile demonstrated in the trial?
“No new signal emerged, which is reassuring.”